Literature DB >> 18184704

Increased cytotoxic T-lymphocyte epitope variant cross-recognition and functional avidity are associated with hepatitis C virus clearance.

Daniel Yerly1, David Heckerman, Todd M Allen, John V Chisholm, Kellie Faircloth, Caitlyn H Linde, Nicole Frahm, Joerg Timm, Werner J Pichler, Andreas Cerny, Christian Brander.   

Abstract

Hepatitis C virus (HCV) clearance has been associated with reduced viral evolution in targeted cytotoxic T-lymphocyte (CTL) epitopes, suggesting that HCV clearers may mount CTL responses with a superior ability to recognize epitope variants and prevent viral immune escape. Here, 40 HCV-infected subjects were tested with 406 10-mer peptides covering the vast majority of the sequence diversity spanning a 197-residue region of the NS3 protein. HCV clearers mounted significantly broader CTL responses of higher functional avidity and with wider variant cross-recognition capacity than nonclearers. These observations have important implications for vaccine approaches that may need to induce high-avidity responses in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18184704      PMCID: PMC2258967          DOI: 10.1128/JVI.02252-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL.

Authors:  M Derby; M Alexander-Miller; R Tse; J Berzofsky
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

2.  Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses.

Authors:  Florian Bihl; Nicole Frahm; Loriana Di Giammarino; John Sidney; Mina John; Karina Yusim; Tonia Woodberry; Kaori Sango; Hannah S Hewitt; Leah Henry; Caitlyn H Linde; John V Chisholm; Tauheed M Zaman; Eunice Pae; Simon Mallal; Bruce D Walker; Alessandro Sette; Bette T Korber; David Heckerman; Christian Brander
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

3.  Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses.

Authors:  Rika Draenert; Marcus Altfeld; Christian Brander; Nesli Basgoz; Colleen Corcoran; Alysse G Wurcel; David R Stone; Spyros A Kalams; Alicja Trocha; Marylyn M Addo; Philip J R Goulder; Bruce D Walker
Journal:  J Immunol Methods       Date:  2003-04-01       Impact factor: 2.303

4.  CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained.

Authors:  F Lechner; N H Gruener; S Urbani; J Uggeri; T Santantonio; A R Kammer; A Cerny; R Phillips; C Ferrari; G R Pape; P Klenerman
Journal:  Eur J Immunol       Date:  2000-09       Impact factor: 5.532

5.  Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation.

Authors:  Karina Yusim; Can Kesmir; Brian Gaschen; Marylyn M Addo; Marcus Altfeld; Søren Brunak; Alexandre Chigaev; Vincent Detours; Bette T Korber
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

6.  Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection.

Authors:  H M Diepolder; R Zachoval; R M Hoffmann; E A Wierenga; T Santantonio; M C Jung; D Eichenlaub; G R Pape
Journal:  Lancet       Date:  1995-10-14       Impact factor: 79.321

7.  The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes.

Authors:  A L Erickson; Y Kimura; S Igarashi; J Eichelberger; M Houghton; J Sidney; D McKinney; A Sette; A L Hughes; C M Walker
Journal:  Immunity       Date:  2001-12       Impact factor: 31.745

8.  Clonal selection, clonal senescence, and clonal succession: the evolution of the T cell response to infection with a persistent virus.

Authors:  Miles P Davenport; Chrysoula Fazou; Andrew J McMichael; Margaret F C Callan
Journal:  J Immunol       Date:  2002-04-01       Impact factor: 5.422

9.  Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot"

Authors:  Florian K Bihl; Elisabetta Loggi; John V Chisholm; Hannah S Hewitt; Leah M Henry; Caitlyn Linde; Todd J Suscovich; Johnson T Wong; Nicole Frahm; Pietro Andreone; Christian Brander
Journal:  J Transl Med       Date:  2005-05-11       Impact factor: 5.531

10.  Analysis of successful immune responses in persons infected with hepatitis C virus.

Authors:  F Lechner; D K Wong; P R Dunbar; R Chapman; R T Chung; P Dohrenwend; G Robbins; R Phillips; P Klenerman; B D Walker
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

View more
  27 in total

1.  Distinct Escape Pathway by Hepatitis C Virus Genotype 1a from a Dominant CD8+ T Cell Response by Selection of Altered Epitope Processing.

Authors:  Andreas Walker; Kathrin Skibbe; Eike Steinmann; Stephanie Pfaender; Thomas Kuntzen; Dominik A Megger; Svenja Groten; Barbara Sitek; Georg M Lauer; Arthur Y Kim; Thomas Pietschmann; Todd M Allen; Joerg Timm
Journal:  J Virol       Date:  2015-10-07       Impact factor: 5.103

2.  High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control.

Authors:  Christoph T Berger; Nicole Frahm; David A Price; Beatriz Mothe; Musie Ghebremichael; Kari L Hartman; Leah M Henry; Jason M Brenchley; Laura E Ruff; Vanessa Venturi; Florencia Pereyra; John Sidney; Alessandro Sette; Daniel C Douek; Bruce D Walker; Daniel E Kaufmann; Christian Brander
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

3.  Synthetic antigens representing the antigenic variation of human hepatitis C virus.

Authors:  Kyung Hee Kang; Yasuhiro Yamamura; Maria P Carlos; Nicolas Karvelas; In-Sup Kim; Deepa Sunkara; Rebecca Rivera; Murray B Gardner; David E Anderson; Francisco Diaz-Mitoma; José Torres; Juan P Marquez
Journal:  Viral Immunol       Date:  2010-10       Impact factor: 2.257

4.  TCR-ligand dissociation rate is a robust and stable biomarker of CD8+ T cell potency.

Authors:  Mathilde Allard; Barbara Couturaud; Laura Carretero-Iglesia; Minh Ngoc Duong; Julien Schmidt; Gwennaëlle C Monnot; Pedro Romero; Daniel E Speiser; Michael Hebeisen; Nathalie Rufer
Journal:  JCI Insight       Date:  2017-07-20

5.  Immune response of cytotoxic T lymphocytes and possibility of vaccine development for hepatitis C virus infection.

Authors:  Kazumasa Hiroishi; Junichi Eguchi; Shigeaki Ishii; Ayako Hiraide; Masashi Sakaki; Hiroyoshi Doi; Risa Omori; Michio Imawari
Journal:  J Biomed Biotechnol       Date:  2010-05-20

6.  The use of fluorescent target arrays for assessment of T cell responses in vivo.

Authors:  Benjamin J C Quah; Danushka K Wijesundara; Charani Ranasinghe; Christopher R Parish
Journal:  J Vis Exp       Date:  2014-06-19       Impact factor: 1.355

Review 7.  Molecular and contextual markers of hepatitis C virus and drug abuse.

Authors:  Paul Shapshak; Charurut Somboonwit; Lydia N Drumright; Simon D W Frost; Deborah Commins; Timothy L Tellinghuisen; William K Scott; Robert Duncan; Clyde McCoy; J Bryan Page; Brian Giunta; Francisco Fernandez; Elyse Singer; Andrew Levine; Alireza Minagar; Oluwadayo Oluwadara; Taiwo Kotila; Francesco Chiappelli; John T Sinnott
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

8.  Design, expression, and processing of epitomized hepatitis C virus-encoded CTL epitopes.

Authors:  Daniel Yerly; David Heckerman; Todd Allen; Todd J Suscovich; Nebojsa Jojic; Carl Kadie; Werner J Pichler; Andreas Cerny; Christian Brander
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

9.  The evolutionary dynamics of a rapidly mutating virus within and between hosts: the case of hepatitis C virus.

Authors:  Fabio Luciani; Samuel Alizon
Journal:  PLoS Comput Biol       Date:  2009-11-13       Impact factor: 4.475

10.  Sang Froid in a time of trouble: is a vaccine against HIV possible?

Authors:  Stanley A Plotkin
Journal:  J Int AIDS Soc       Date:  2009-02-02       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.